中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

62 records (took 0.023 seconds)

    METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS
    1.
    发明申请
    METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS 审中-公开
    用于放大丙型肝炎病毒核酸的方法

    公开(公告)号：WO2010090857A3

    公开(公告)日：2010-11-25

    申请号：PCT/US2010021589

    申请日：2010-01-21

    Applicant: VERTEX PHARMA ,  KWONG ANN D ,  FRANTZ JAMES DANIEL ,  BARTELS DOUGLAS J ,  LIN CHAO ,  SHAMES BENJAMIN ,  SEEPERSAUD SHEILA ,  LIPPKE JUDITH A ,  KIEFFER TARA L ,  ZHOU YI ,  ZHANG EILEEN Z ,  SULLIVAN JAMES C

    Inventor： KWONG ANN D ,  FRANTZ JAMES DANIEL ,  BARTELS DOUGLAS J ,  LIN CHAO ,  SHAMES BENJAMIN ,  SEEPERSAUD SHEILA ,  LIPPKE JUDITH A ,  KIEFFER TARA L ,  ZHOU YI ,  ZHANG EILEEN Z ,  SULLIVAN JAMES C

    IPC: C12Q1/68

    CPC classification number: C12Q1/707 ,  C12Q1/6883

    Abstract: A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.

    Abstract translation: 在HCV感染样品中扩增HCV核酸的方法包括通过两阶段PCR从样品中扩增与HCV RNA基因组互补的DNA模板的片段，其中第一阶段PCR使用第一外部引物 和第二外引物，第二阶段PCR采用第一内引物和第二内引物。 第一外引物的核苷酸序列包含SEQ ID NO：2所示的核苷酸序列; 或SEQ ID NO：9，其中任选地1,2或3个核苷酸是比SEQ ID NO：9的核苷酸更多的核苷酸。第二外部引物的核苷酸序列包含SEQ ID NO：3或4所示的核苷酸序列; 或如SEQ ID NO：10或11所示的核苷酸序列，其中任选1,2或3个核苷酸是与SEQ ID NO：10和11相同的其它核苷酸。第一内引物的核苷酸序列包含核苷酸序列 如SEQ ID NO：5所示; 或SEQ ID NO：12，其中任选地1,2或3个核苷酸是与SEQ ID NO：12相同的其它核苷酸。第二内引物的核苷酸序列包含SEQ ID NO：6或7所示的核苷酸序列 ; 或如SEQ ID NO：13或14所示的核苷酸序列，其中任选地1,2或3个核苷酸是与SEQ ID NO：13和14相同的其它核苷酸。

    METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS
    2.
    发明申请
    METHODS FOR AMPLIFYING HEPATITIS C VIRUS NUCLEIC ACIDS 审中-公开
    用于放大丙型肝炎病毒核酸的方法

    公开(公告)号：WO2010090857A8

    公开(公告)日：2012-06-28

    申请号：PCT/US2010021589

    申请日：2010-01-21

    Applicant: VERTEX PHARMA ,  KWONG ANN D ,  FRANTZ JAMES DANIEL ,  BARTELS DOUGLAS J ,  LIN CHAO ,  SHAMES BENJAMIN ,  SEEPERSAUD SHEILA ,  LIPPKE JUDITH A ,  KIEFFER TARA L ,  ZHOU YI ,  ZHANG EILEEN Z ,  SULLIVAN JAMES C

    Inventor： KWONG ANN D ,  FRANTZ JAMES DANIEL ,  BARTELS DOUGLAS J ,  LIN CHAO ,  SHAMES BENJAMIN ,  SEEPERSAUD SHEILA ,  LIPPKE JUDITH A ,  KIEFFER TARA L ,  ZHOU YI ,  ZHANG EILEEN Z ,  SULLIVAN JAMES C

    IPC: C12Q1/68

    CPC classification number: C12Q1/707 ,  C12Q1/6883

    Abstract: A method of amplifying an HCV nucleic acid in an HCV infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR, wherein a first stage PCR employs a first outer primer and a second outer primer, and a second stage PCR employs a first inner primer and a second inner primer. The nucleotide sequence of the first outer primer comprises a nucleotide sequence as set forth in SEQ ID NO: 2; or SEQ ID NO:9, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 9. The nucleotide sequence of the second outer primer comprises a nucleotide sequence set forth in SEQ ID NO: 3 or 4; or a nucleotide sequence as set forth in SEQ ID NO: 10 or 11, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 10 and 11. The nucleotide sequence of the first inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 5; or SEQ ID NO: 12, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 12. The nucleotide sequence of the second inner primer comprises a nucleotide sequence as set forth in SEQ ID NO: 6 or 7; or a nucleotide sequence as set forth in SEQ ID NO: 13 or 14, wherein optionally 1, 2 or 3 nucleotides are other nucleotides than those of SEQ ID NO: 13 and 14.

    Abstract translation: 在HCV感染样品中扩增HCV核酸的方法包括通过两阶段PCR从样品中扩增与HCV RNA基因组互补的DNA模板的片段，其中第一阶段PCR使用第一外部引物 和第二外引物，第二阶段PCR采用第一内引物和第二内引物。 第一外引物的核苷酸序列包含SEQ ID NO：2所示的核苷酸序列; 或SEQ ID NO：9，其中任选地1,2或3个核苷酸是比SEQ ID NO：9的核苷酸更多的核苷酸。第二外部引物的核苷酸序列包含SEQ ID NO：3或4所示的核苷酸序列; 或如SEQ ID NO：10或11所示的核苷酸序列，其中任选1,2或3个核苷酸是与SEQ ID NO：10和11相同的其它核苷酸。第一内引物的核苷酸序列包含核苷酸序列 如SEQ ID NO：5所示; 或SEQ ID NO：12，其中任选地1,2或3个核苷酸是与SEQ ID NO：12相同的其它核苷酸。第二内引物的核苷酸序列包含SEQ ID NO：6或7所示的核苷酸序列 ; 或如SEQ ID NO：13或14所示的核苷酸序列，其中任选地1,2或3个核苷酸是与SEQ ID NO：13和14相同的其它核苷酸。

    COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION
    3.
    发明申请
    COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION 审中-公开
    用于治疗HCV感染的联合治疗

    公开(公告)号：WO2008137126A3

    公开(公告)日：2009-04-09

    申请号：PCT/US2008005758

    申请日：2008-05-05

    Applicant: VERTEX PHARMA ,  KWONG ANN ,  MANI NAGRAJ ,  ZHOU YI ,  LIN CHAO

    Inventor： KWONG ANN ,  MANI NAGRAJ ,  ZHOU YI ,  LIN CHAO

    IPC: A61K45/06 ,  A61K31/7068 ,  A61P31/12

    CPC classification number: A61K31/497 ,  A61K31/7068 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.

    Abstract translation: 本发明涉及包含用于治疗HCV的蛋白酶抑制剂和聚合酶抑制剂的治疗组合。 本发明还涉及包含VX-950和聚合酶抑制剂的治疗组合。 也在本发明的范围内的方法是使用本发明的治疗组合治疗HCV感染或减轻患者中的一种或多种症状的方法。 本发明还提供包含本发明组合的试剂盒。

Patent Agency Ranking